| Literature DB >> 21037584 |
Yong Xu1, Eric D Berglund, Jong-Woo Sohn, William L Holland, Jen-Chieh Chuang, Makoto Fukuda, Jari Rossi, Kevin W Williams, Juli E Jones, Jeffrey M Zigman, Bradford B Lowell, Philipp E Scherer, Joel K Elmquist.
Abstract
Mice lacking 5-HT 2C receptors (5-HT(2C)Rs) displayed hepatic insulin resistance, a phenotype normalized by re-expression of 5-HT(2C)Rs only in pro-opiomelanocortin (POMC) neurons. 5-HT(2C)R deficiency also abolished the anti-diabetic effects of meta-chlorophenylpiperazine (a 5-HT(2C)R agonist); these effects were restored when 5-HT(2C)Rs were re-expressed in POMC neurons. Our findings indicate that 5-HT(2C)Rs expressed by POMC neurons are physiologically relevant regulators of insulin sensitivity and glucose homeostasis in the liver.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21037584 PMCID: PMC3059249 DOI: 10.1038/nn.2664
Source DB: PubMed Journal: Nat Neurosci ISSN: 1097-6256 Impact factor: 24.884
Figure 1mCPP-induced depolarization of POMC neurons is abolished in 2C null mice, but restored in 2C/POMC mice. (a) Whole-cell capacitance and resting membrane potential of POMC neurons. The numbers of cells recorded are indicated in the parentheses. (b) mCPP-induced changes in membrane potential (ΔmCPP) from all recorded POMC neurons (left bars) and depolarized POMC neurons only (right bars). *, P<0.05. (c) The percentage of POMC neurons that depolarized in response to mCPP. (d) Representative membrane potential traces. Horizontal bars indicate the period of mCPP treatment. Dotted lines indicate the resting membrane potential. Scale bars indicate 10 mV (vertical) and 30 s (horizontal). All data are presented as mean ± s.e.m.
Figure 2Re-expression of 5-HT2CRs in POMC neurons rescues insulin resistance. (a) Insulin tolerance tests in chow-fed mice (insulin 1 U/kg). N=8 or 9/genotype. * or ***, P<0.05 or P<0.001 between 2C null vs WT mice; # or ###, P<0.05 or P<0.001 between 2C null vs 2C/POMC mice. (b) Glucose tolerance tests in chow-fed mice (glucose 1 g/kg). N=5–12/genotype. (c) Serum glucose at fed or fasted conditions in chow-fed mice. N=6–12/genotype. (d) Serum insulin at fed or fasted conditions in chow-fed mice. N=12–23/genotype. (e) Serum insulin at 30 min after HFD-fed mice received a glucose bolus injection (0.75 g/kg). N=6–14/genotype. * or **, P<0.05 or P<0.01. (f) Glucose infusion rate during a hyperinsulinemic-euglycemic clamp in chow-fed mice. N=7–9/genotype. *, ** or ***, P<0.05, P<0.01 or P<0.001 between 2C null vs WT mice; #, ## or ###, P<0.05, P<0.01 or P<0.001 between 2C null vs 2C/POMC mice. (g) Hepatic glucose production at basal (pre-clamp) or hyperinsulinemic clamp conditions. N=7–9/genotype. * or ***, P<0.05 or P<0.001. (h) Glucose disposal rate at basal (pre-clamp) or hyperinsulinemic clamp conditions. N=7–9/genotype. *, P<0.05. (i) Intraperitoneal injections of saline or mCPP (1.5 mg/kg), followed by GTT (0.75 g/kg) in WT, 2C null and 2C/POM mice. (j) Intraperitoneal injections of saline or mCPP (1.5 mg/kg), followed by ITT (1.5 U/kg) in WT, 2C null and 2C/POM mice. N=8–9/group. *, ** or ***, P<0.05, P<0.01 or P<0.001 between saline vs mCPP. All data are presented as mean ± s.e.m. Care of all animals and procedures were approved by UTSW Institutional Animal Care and Use Committees.